Pages that link to "Q34663361"

The following pages link to Donepezil Use in Alzheimer Disease (Q34663361):

Displaying 39 items.

• Donepezil (Aricept) for treatment of Alzheimer's disease and other dementing conditions (Q30436664) (← links)
• Cholinesterase inhibitors: a therapeutic strategy for Alzheimer disease (Q33637687) (← links)
• Donepezil in treatment-resistant bipolar disorder. (Q33673659) (← links)
• Donepezil. Pharmacoeconomic implications of therapy (Q33761849) (← links)
• Donepezil: a review of its use in Alzheimer's disease (Q33914241) (← links)
• Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors (Q34142818) (← links)
• Rivastigmine for Alzheimer's disease: Canadian interpretation of intermediate outcome measures and cost implications (Q34147264) (← links)
• Ion channel diseases of the central nervous system. (Q34320159) (← links)
• Unveiling clusters of RNA transcript pairs associated with markers of Alzheimer's disease progression. (Q34429308) (← links)
• Donepezil for Alzheimer's disease: pharmacodynamic, pharmacokinetic, and clinical profiles. (Q34519657) (← links)
• New insights into the structural characteristics and functional relevance of the human cytochrome P450 2D6 enzyme (Q34994964) (← links)
• Rivastigmine in vascular dementia (Q35784086) (← links)
• Pharmacologic treatment of adolescent and child schizophrenia (Q36107249) (← links)
• Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I. (Q37611786) (← links)
• Symptomatic treatment of Alzheimer's disease: identification of biomarkers to aid translation from bench to bedside (Q37755138) (← links)
• Pharmacologic Treatment of Apathy in Dementia (Q37917417) (← links)
• Cholinesterase inhibitors for the treatment of Alzheimer's disease:: getting on and staying on. (Q38221488) (← links)
• Propargylamine as functional moiety in the design of multifunctional drugs for neurodegenerative disorders: MAO inhibition and beyond (Q38447289) (← links)
• Synthesis, pharmacological assessment, and molecular modeling of acetylcholinesterase/butyrylcholinesterase inhibitors: effect against amyloid-β-induced neurotoxicity. (Q39199947) (← links)
• Donepezil dose-dependently inhibits acetylcholinesterase activity in various areas and in the presynaptic cholinergic and the postsynaptic cholinoceptive enzyme-positive structures in the human and rat brain (Q42495563) (← links)
• Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II. (Q43244977) (← links)
• Do CYP3A and ABCB1 genotypes influence the plasma concentration and clinical outcome of donepezil treatment? (Q43791088) (← links)
• Impact of CYP2D6 and CYP3A4 genetic polymorphism on combined cholinesterase inhibitors and memantine treatment in mild to moderate Alzheimer's disease (Q44029128) (← links)
• beta-Amyloid aggregation induced by human acetylcholinesterase: inhibition studies (Q44277892) (← links)
• Aromatic amino‐acid residues at the active and peripheral anionic sites control the binding of E2020 (Aricept®) to cholinesterases (Q44658338) (← links)
• Risk of antipsychotic drug use in patients with Alzheimer's disease treated with rivastigmine (Q44844450) (← links)
• Donepezil use in US nursing homes. (Q44887370) (← links)
• Donepezil in the treatment of ADHD-like symptoms in youths with pervasive developmental disorder: a case series (Q46947275) (← links)
• Recipient treatment with acetylcholinesterase inhibitor donepezil attenuates primary graft failure in rats through inhibiting post-transplantational donor heart ischaemia/reperfusion injury (Q48649848) (← links)
• Concurrent administration of atypical antipsychotics and donepezil: drug interaction study in rats (Q48677854) (← links)
• Pharmacokinetic Comparison of Orally Disintegrating and Conventional Donepezil Formulations in Healthy Korean Male Subjects: A Single-Dose, Randomized, Open-Label, 2-Sequence, 2-Period Crossover Study (Q51371251) (← links)
• Silymarin attenuated the amyloid β plaque burden and improved behavioral abnormalities in an Alzheimer's disease mouse model (Q51829034) (← links)
• Impact of the CYP2D6 polymorphism on steady-state plasma concentrations and clinical outcome of donepezil in Alzheimer's disease patients (Q51914746) (← links)
• Efficacy and safety of a loading-dose regimen versus a no-loading-dose regimen of metrifonate in the symptomatic treatment of Alzheimer's disease: a randomized, double-masked, placebo-controlled trial. Metrifonate Study Group (Q51986327) (← links)
• Pharmacokinetics of the M1-agonist talsaclidine in mouse, rat, rabbit and monkey, and extrapolation to man. (Q53238361) (← links)
• Cholinesterase inhibitors in the treatment of Alzheimer's disease: a comparison of tolerability and pharmacology. (Q53333243) (← links)
• Kinetics of human acetylcholinesterase inhibition by the novel experimental Alzheimer therapeutic agent, tolserine. (Q53341753) (← links)
• Inhibitory effects of donepezil hydrochloride (E2020) on cholinesterase activity in brain and peripheral tissues of young and aged rats (Q73302837) (← links)
• [Myocardial ischemia in a female patient treated with donepezil] (Q73878780) (← links)